Jeffrey Casavant

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text

Medicine, Immunology, Pharmacology +17

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 335 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Identification of <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

Michael L. Vazquez, Neelu Kaila, Joseph W. Strohbach et al. · Journal of Medicinal Chemistry · 2018 · 171 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Preparation, Gram-Negative Antibacterial Activity, and Hydrolytic Stability of Novel Siderophore-Conjugated Monocarbam Diols

Mark E. Flanagan, Steven J. Brickner, Manjinder S. Lall et al. · ACS Medicinal Chemistry Letters · 2011 · 71 citations

Life Sciences, Medicinal Chemistry, Pharmacology +17

Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism

L. Nathan Tumey, Carolyn A. Leverett, Beth C. Vetelino et al. · ACS Medicinal Chemistry Letters · 2016 · 70 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17